InsidersTradesSigma
申报总数
公司
▲ 买入（2 笔）
▼ 卖出（1 笔）
内部人交易记录
首席财务官已披露买入
2
已披露卖出
1
T+90 胜率
100%
T+90 平均收益
+17.4%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Browse the complete record of transactions filed by Doyle Anthony, 首席财务官. Director active across 1 company, notably Biocryst Pharmaceuticals INC. Cumulatively, 11 reports have been logged. Breakdown: 2 buys · 1 sell. Total volume traded: €637k. Activity tracked since 23 November 2021. The latest transaction was filed on 19 December 2024 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Doyle Anthony
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报11 总计
120,700 股0Common StockSEC:0001127602-24-029965:0
2,461 股@ US$7.391.6% 占其流量Common StockSEC:0001127602-24-029965:1
7,890 股@ US$7.535.1% 占其流量Common StockSEC:0001127602-24-029573:0
36,300 股@ US$5.5716.8% 占其流量Common StockSEC:0001127602-24-015373:0
标准退出：2024年8月12日 (T+90)
2,482 股@ US$6.051.2% 占其流量Common StockSEC:0001127602-23-030181:0
34,000 股0Common StockSEC:0001127602-23-029831:0
34,000 股0Common StockSEC:0001127602-22-028074:0
5,700 股@ US$10.905.2% 占其流量Common StockSEC:0001127602-22-027883:0
75,000 股0Common StockSEC:0001127602-22-001456:0
115,000 股0Common StockSEC:0001127602-21-031121:0
35,258 股@ US$12.4854.0% 占其流量Common StockSEC:0001171843-21-008176:0
标准退出：2022年2月21日 (T+90)
11 条申报中的 11 条
About Doyle Anthony
Doyle Anthony is Chief Financial Officer at Biocryst Pharmaceuticals INC (XNAS). He has 11 filings in total, and across the sampled recent filings they span 2021-11-24 to 2024-12-23, with buy amounts of EUR 578364 and sell amounts of EUR 58194; the modal transaction nature is Attribution.
